The company is set to announce its latest quarterly earnings on Wednesday, April 29th, with a consensus estimate of $1.97 earnings per share.
Bio-Rad Laboratories, Inc. is currently priced at $278.9 with a decrease of $8.39 (-2.92%) from the previous close. Trading volume is at $45,967, representing a 15.53% increase compared to the average.
In the last earnings report on Wednesday, February 11th, the company reported earnings per share of $2.51, slightly below the consensus estimate of $2.57.
The company experienced a net change in cash of $132.00 million, ending the period with $529.80 million in cash. Operating cash flow stood at $164.9 million.
Bio-Rad Laboratories generated revenue of $693.2 million, resulting in a net income of $720 million. Earnings per share were reported at $26.69, with an EBITDA of $114.3 million.
Key ratios include a net profit margin of 103.87%, return on equity of 9.66%, and a price to earnings ratio of 2.84.
The company holds total assets of $10.58 billion, with total liabilities at $3.12 billion. Cash and cash equivalents amount to $531.80 million.
This financial snapshot highlights Bio-Rad Laboratories, Inc.'s performance and financial health in the current trading session.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.